Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20475967 | 1.00 | LMNA (0.47) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL29921999 | 0.82 | RIPK1 (0.34) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL14935542 | 0.81 | LMNA (0.44) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL14935540 | 0.81 | LMNA (0.44) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL28434224 | 0.79 | RIPK1 (0.44) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL1726185 | 0.77 | TSHR (0.46) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL22095153 | 0.76 | CYP2C19 (0.47) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL21080319 | 0.76 | LMNA (0.39) | LMNARIPK1KMT2AMEN1HTT | |
| SCHEMBL27893367 | 0.76 | ATM (0.45) | LMNAKMT2AMEN1HTTL3MBTL1 | |
| SCHEMBL9397678 | 0.75 | RIPK1 (0.46) | LMNARIPK1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123537-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | AUROBINDO PHARMA LTD. (IN) | 2013-05-16 | — | — | US | disclosed |
| WO-2011144983-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE | AUROBINDO PHARMA LIMITED (IN) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123537-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | MYT1, TET1, LPXN | LMNA 878/4885RIPK1 3155/4885KMT2A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.